Marker Therapeutics Inc (MRKR)

$1.42 +0.15 (11.81%)
Market Cap 19.84M
Revenue (ttm) 6.59M
Net Income (ttm) -10.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -162.82%
Debt to Equity Ratio 0.00
Volume 506,300
Avg Vol 263,472
Day's Range N/A - N/A
Shares Out 16.67M
Stochastic %K 98%
Beta 1.35
Analysts Strong Sell
Price Target $8.17

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 400 6400
Address:
2450 Holcombe Blvd, MS: BCM251, Houston, United States
WhereAmIGoing
WhereAmIGoing Dec. 5 at 12:59 AM
$MRKR beat the 52w high - you’ve got this!
0 · Reply
Awesom69Trade
Awesom69Trade Dec. 4 at 10:07 PM
$MRKR technical is ready for breakout run like Forest Gump! We need that 500% pop before xmas! Imo
0 · Reply
aperzy20
aperzy20 Dec. 4 at 8:57 PM
$MRKR ok im excited! somethings brewing
0 · Reply
BULLTRADER0007
BULLTRADER0007 Dec. 4 at 8:55 PM
$MRKR Tomorrow it’s a big day,anticipate it before you chase it
0 · Reply
itsMeRich
itsMeRich Dec. 4 at 7:51 PM
$MRKR this is very interesting, that the shorts are leaving this alone for some reason
0 · Reply
birddogsfly
birddogsfly Dec. 4 at 7:45 PM
$MRKR hmm
0 · Reply
SimSimBola
SimSimBola Dec. 4 at 7:34 PM
$MRKR Not a bear in sight. sudden death is the worst.😶
0 · Reply
aperzy20
aperzy20 Dec. 4 at 6:46 PM
$MRKR boom!! lets keep it going!
0 · Reply
johnny6nine
johnny6nine Dec. 4 at 6:45 PM
$MRKR climbing back up, day after day. Love it
0 · Reply
dwaslimit1
dwaslimit1 Dec. 4 at 5:07 PM
$MRKR pfizer taking a stake?
1 · Reply
Latest News on MRKR
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 7:00 AM EST - 20 days ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 5, 2025, 7:30 AM EST - 4 weeks ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Nov 3, 2025, 9:15 AM EST - 4 weeks ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Oct 6, 2025, 7:30 AM EDT - 2 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 3 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Aug 26, 2025, 12:34 PM EDT - 3 months ago

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Aug 26, 2025, 7:00 AM EDT - 3 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:00 AM EDT - 4 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Jun 17, 2025, 8:00 AM EDT - 6 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 7 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025, 8:00 AM EDT - 7 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Mar 31, 2025, 8:45 AM EDT - 8 months ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 7:00 AM EST - 10 months ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 19, 2024, 8:05 AM EST - 1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 17, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15, 2024, 4:15 PM EDT - 1 year ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 25, 2024, 5:45 PM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 22, 2024, 12:30 PM EDT - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 22, 2024, 7:30 AM EST - 2 years ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 5:00 PM EST - 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 31, 2023, 6:30 AM EDT - 2 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 8, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

May 1, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Mar 22, 2023, 8:10 AM EDT - 2 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Dec 13, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Aug 4, 2022, 4:37 PM EDT - 3 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

May 4, 2022, 10:30 AM EDT - 3 years ago

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Mar 17, 2022, 5:45 PM EDT - 4 years ago

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

WhereAmIGoing
WhereAmIGoing Dec. 5 at 12:59 AM
$MRKR beat the 52w high - you’ve got this!
0 · Reply
Awesom69Trade
Awesom69Trade Dec. 4 at 10:07 PM
$MRKR technical is ready for breakout run like Forest Gump! We need that 500% pop before xmas! Imo
0 · Reply
aperzy20
aperzy20 Dec. 4 at 8:57 PM
$MRKR ok im excited! somethings brewing
0 · Reply
BULLTRADER0007
BULLTRADER0007 Dec. 4 at 8:55 PM
$MRKR Tomorrow it’s a big day,anticipate it before you chase it
0 · Reply
itsMeRich
itsMeRich Dec. 4 at 7:51 PM
$MRKR this is very interesting, that the shorts are leaving this alone for some reason
0 · Reply
birddogsfly
birddogsfly Dec. 4 at 7:45 PM
$MRKR hmm
0 · Reply
SimSimBola
SimSimBola Dec. 4 at 7:34 PM
$MRKR Not a bear in sight. sudden death is the worst.😶
0 · Reply
aperzy20
aperzy20 Dec. 4 at 6:46 PM
$MRKR boom!! lets keep it going!
0 · Reply
johnny6nine
johnny6nine Dec. 4 at 6:45 PM
$MRKR climbing back up, day after day. Love it
0 · Reply
dwaslimit1
dwaslimit1 Dec. 4 at 5:07 PM
$MRKR pfizer taking a stake?
1 · Reply
Selett
Selett Dec. 4 at 4:28 PM
$MRKR let’s get over $1.4 and see some big volume. That’ll send it
0 · Reply
SimSimBola
SimSimBola Dec. 4 at 1:36 PM
$MRKR $CAPR yes,short a third of float. but then you have to dream on two things: the stock rises to $6 first and Juan actually have some meaningful PR to release.
1 · Reply
plavac
plavac Dec. 4 at 1:29 PM
$MRKR
0 · Reply
aperzy20
aperzy20 Dec. 4 at 1:03 PM
$MRKR
0 · Reply
Awesom69Trade
Awesom69Trade Dec. 3 at 9:53 PM
$MRKR can we do like $CAPR ?
0 · Reply
Awesom69Trade
Awesom69Trade Dec. 3 at 6:27 PM
$MRKR new intraday high broke $1.26 level. Now we gonna ride high with Rudolph.
1 · Reply
SimSimBola
SimSimBola Dec. 3 at 3:21 AM
$PLRZ $MRKR because it simply isnt valid. he aint called bulltrader for nothing except missing the word sh!t. should be called bullsh!trader. 1-6 reverse split preceded by 1-250 in May. that company plrz is borderline a rip off. some nerve to dare compare to mrkr.
0 · Reply
Awesom69Trade
Awesom69Trade Dec. 3 at 12:10 AM
$MRKR Santa, where are you? We need you for rally
1 · Reply
iholdTNXPbutIhateSeth
iholdTNXPbutIhateSeth Dec. 2 at 7:21 PM
$MRKR I'm bored,
0 · Reply
BULLTRADER0007
BULLTRADER0007 Dec. 2 at 6:15 PM
$MRKR = $PLRZ If the price exceeds 1.30, this will become NHOD
1 · Reply
BULLTRADER0007
BULLTRADER0007 Dec. 2 at 12:33 PM
$MRKR ⌛️
0 · Reply
Viperwilder
Viperwilder Dec. 1 at 4:52 PM
$MRKR this looks fire but until next week it stays low
1 · Reply